Endodiag

Executive Summary

Endodiag is a French diagnostics company dedicated to improving the detection and characterization of endometriosis, a condition affecting millions of women worldwide. Founded in 2012 and headquartered in Paris, the company develops innovative screening solutions that enable healthcare professionals to tailor treatment strategies based on individual patient profiles. By focusing on early diagnosis and personalized medicine, Endodiag aims to address a significant unmet medical need, as endometriosis often goes undiagnosed for years due to symptom variability and lack of non-invasive tests. The company's approach combines biomarker research with advanced analytics to create diagnostic tools that can be integrated into routine clinical practice. Despite being in a private stage with no disclosed funding rounds or valuation, Endodiag has established a presence in the competitive diagnostics landscape, leveraging partnerships with research institutions and clinicians. The global endometriosis diagnostics market is expected to grow as awareness increases, positioning Endodiag to capture value if its solutions achieve regulatory clearance and clinical adoption. However, the company faces challenges such as limited financial resources, rigorous regulatory pathways, and competition from established players. With a focused product pipeline and a clear value proposition, Endodiag represents an early-stage opportunity in women's health diagnostics, pending successful validation and commercialization of its technologies.

Upcoming Catalysts (preview)

• Q2 2026CE-IVD marking for lead diagnostic test70% success
• Q4 2026Partnership with major hospital network for clinical validation60% success
• Q3 2026Publication of pivotal study results in peer-reviewed journal80% success